Scarica l'app Stockscreener
7.39
6.64%
0.46
Pre-mercato:
7.40
0.01
+0.14%
Precedente Chiudi:
$6.93
Aprire:
$7.01
Volume 24 ore:
296.35K
Relative Volume:
1.50
Capitalizzazione di mercato:
$217.13M
Reddito:
$1.78M
Utile/perdita netta:
$-151.77M
Rapporto P/E:
-1.2746
EPS:
-5.7981
Flusso di cassa netto:
$-79.40M
1 W Prestazione:
+8.68%
1M Prestazione:
+18.05%
6M Prestazione:
-3.65%
1 anno Prestazione:
-40.59%
Intervallo 1D:
$6.83
$7.46
Intervallo di 1 settimana:
$5.95
$7.46
Portata 52W:
$5.60
$15.57
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Nome
Cartesian Therapeutics Inc
Settore
Industria
Telefono
301-348-8698
Indirizzo
7495 NEW HORIZON WAY, FREDERICK
Compare RNAC vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
7.39 | 217.13M | 1.78M | -151.77M | -79.40M | -5.7981 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-09 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-09 | Iniziato | Wedbush | Outperform |
| 2024-12-19 | Iniziato | BTIG Research | Buy |
| 2024-08-06 | Iniziato | TD Cowen | Buy |
| 2024-07-02 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Iniziato | Oppenheimer | Outperform |
| 2024-05-24 | Iniziato | Mizuho | Buy |
| 2024-04-23 | Reiterato | H.C. Wainwright | Buy |
| 2024-04-23 | Iniziato | Leerink Partners | Outperform |
| 2023-08-18 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Reiterato | Needham | Buy |
| 2022-06-06 | Iniziato | SVB Leerink | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-01-26 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-10-01 | Downgrade | Mizuho | Buy → Neutral |
| 2020-10-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Downgrade | Stifel | Buy → Hold |
| 2020-04-28 | Iniziato | H.C. Wainwright | Buy |
| 2020-01-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Iniziato | William Blair | Outperform |
| 2018-06-27 | Iniziato | Janney | Buy |
| 2017-03-30 | Reiterato | UBS | Buy |
Mostra tutto
Cartesian Therapeutics Inc Borsa (RNAC) Ultime notizie
Cartesian Therapeutics Inc (RNAC) - MSN
Cartesian Therapeutics Announces New Employment Inducement Grants - The Manila Times
Five new Cartesian hires get stock options priced at $6.22 - Stock Titan
CARTESIAN THERAPEUTICS, INC. (RNAC) - MSN
RNAC Reiterated by Cartesian Therapeutics -- Price Target Mainta - GuruFocus
Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC) - MarketBeat
Cartesian Therapeutics (NASDAQ:RNAC) Posts Quarterly Earnings Results - MarketBeat
Cartesian Therapeutics, Inc. Q1 2026 Financial Report: Forward-Looking Statements, Risks, and Financial Results - Minichart
Mizuho Securities Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Cartesian Therapeutics Reports Q1 2026 Financial Results and Advances Descartes-08 Clinical Trials in Autoimmune Diseases - Minichart
Cartesian Therapeutics, Inc. (RNAC) reports Q1 loss, lags revenue estimates - MSN
Myasthenia Gravis Market: Fast-Growing Therapeutics Outlook by 2034 – DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC - Barchart.com
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
8-K: Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updatemoomoo - Moomoo
Cartesian Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Cartesian Therapeutics posts first quarter 2026 financial results and issues business update - Traders Union
Cartesian Therapeutics (RNAC) widens Q1 loss as R&D rises but cash tops $120M - Stock Titan
Deeper Q1 loss as Cartesian (NASDAQ: RNAC) funds Descartes-08 trials - Stock Titan
Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday - MarketBeat
Is Cartesian Therapeutics (RNAC) 1371.4% Overvalued After Q1 202 - GuruFocus
Cartesian Therapeutics | DEFA14A: Others - Moomoo
Cartesian Therapeutics | DEF 14A: Definitive information statements - Moomoo
Form DEFA14A Cartesian Therapeutics, - StreetInsider
Executive pay, director votes and auditor for Cartesian Therapeutics (NASDAQ: RNAC) - Stock Titan
RNAC Technical Analysis | Trend, Signals & Chart Patterns | CARTESIAN THERAPEUTICS INC (NASDAQ:RNAC) - ChartMill
Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet - Seeking Alpha
Is Cartesian Therapeutics (RNAC) stock a good pick for capital allocation | Q4 2025: EPS Misses ViewsDebt Analysis - Xã Thanh Hà
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock? - Yahoo Finance
Cartesian Therapeutics (RNAC) Stock Underweight (Underperforming) 2026-04-20Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Cartesian Therapeutics (RNAC) Stock Abandons Cartesian Therapeutics (RNAC) Stock (Eye on Rally) 2026-04-18Vega Volatility - UBND thành phố Hải Phòng
Cartesian Therapeutics (NASDAQ:RNAC) Trading 10.3% HigherTime to Buy? - MarketBeat
Cartesian Therapeutics (RNAC) Stock Prediction: What's Next (Drops Sharply) 2026-04-15Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight - GlobeNewswire Inc.
Published on: 2026-04-14 00:35:15 - baoquankhu1.vn
Needham Virtual Healthcare Conference features Cartesian Therapeutics fireside chat on cell therapy - Traders Union
Chart Watch: What chart patterns are forming on Cartesian Therapeutics IncGap Up & Long-Term Growth Plans - baoquankhu1.vn
Today's Analyst Ratings: Needham Reiterates Buy Rating for RNAC - GuruFocus
If You Invested $1,000 in Cartesian (RNAC) - Stock Titan
Trust linked to Cartesian Therapeutics (RNAC) converts preferred into common - Stock Titan
Trust linked to RNAC holder Kalayoglu converts preferred into 758,001 common shares - Stock Titan
Cartesian Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Kalayoglu Murat - Moomoo
Near-20% holder updates Cartesian Therapeutics (RNAC) stake and board role - Stock Titan
RNAC SEC FilingsCartesian 10-K, 10-Q, 8-K Forms - Stock Titan
Is Cartesian Therapeutics (RNAC) Stock Good for Beginners | Price at $6.26, Down 2.03%Community Chart Signals - Cổng thông tin điện tử tỉnh Lào Cai
Published on: 2026-04-01 20:53:55 - baoquankhu1.vn
Big Money Moves: Should I invest in Cartesian Therapeutics Inc before earningsEarnings Summary Report & Smart Allocation Stock Tips - baoquankhu1.vn
RNAC Technical Analysis & Stock Price Forecast - Intellectia AI
Inflation Data: Does Cartesian Therapeutics Inc have declining or rising EPSMarket Weekly Review & Technical Buy Zone Confirmation - baoquankhu1.vn
Cartesian Therapeutics Announces Board Member Murat Kalayoglu Resignation - The Globe and Mail
Cartesian Therapeutics Inc Azioni (RNAC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):